Contents
pdf Download PDF
pdf Download XML
80 Views
13 Downloads
Share this article
Research Article | Volume 12 Issue 11 (November, 2026) | Pages 401 - 416
Role of Hematological and Coagulation Parameters as a Predictor of In-Hospital Mortality and Morbidity in ACS Patients
 ,
 ,
1
Assistant Professor, Department Of Cardiology, SCB Medical College and Hospital, Cuttack, Odisha,
2
Associate Professor, Department Of Orthopedic PRM Medical College and Hospital, Baripada, Odisha,
3
Assistant Professor, Department of Anaesthesiology, SCB Medical College and Hospital, Cuttack, Odisha,
Under a Creative Commons license
Open Access
Received
Oct. 11, 2026
Revised
Oct. 22, 2026
Accepted
Nov. 3, 2026
Published
Nov. 19, 2026
Abstract
Keywords
INTRODUCTION
Acute Coronary Syndrome (ACS), encompassing ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI), and unstable angina (UA), represents a critical and life-threatening manifestation of coronary artery disease (CAD). Globally, cardiovascular diseases are the number one cause of death, and the burden is particularly profound in developing nations like India. The primary pathophysiological mechanism underlying ACS involves the rupture or erosion of an atherosclerotic plaque, leading to platelet activation, coagulation cascade initiation, and subsequent partial or complete occlusion of the coronary artery. Because the interplay between systemic inflammation and localized thrombosis dictates the clinical course of the disease, biomarkers reflecting these processes are of immense prognostic value. While cardiac troponins remain the gold standard for diagnosing myocardial infarction, they are markers of existing necrosis rather than predictive markers of the ongoing prothrombotic state. Therefore, there is a compelling need for early, cost-effective, and widely available prognostic markers to stratify patient risk at the time of admission. Routine complete blood counts (CBC) and coagulation profiles serve this purpose effectively. Parameters such as Total Leukocyte Count (TLC), Mean Platelet Volume (MPV), and the Neutrophil-to-Lymphocyte Ratio (NLR) reflect the inflammatory and prothrombotic milieu. Larger platelets, indicated by a high MPV, are metabolically and enzymatically more active, possessing a higher thrombotic potential. Furthermore, elevated NLR acts as a composite indicator of acute systemic inflammation (neutrophilia) and physiological stress (lymphopenia). Concurrently, the coagulation cascade's hyperactivation can be monitored via parameters like Prothrombin Time (PT), Activated Partial Thromboplastin Time (aPTT), Fibrinogen, and D-dimer. High levels of Fibrinogen promote platelet aggregation and increase blood viscosity, while D-dimer serves as a direct marker of active coagulation and fibrinolysis. Despite the widespread availability of these tests, their combined predictive utility in a localized clinical setting requires continuous validation to optimize risk stratification protocols. The present study was designed to evaluate the role of these routine hematological and coagulation parameters in predicting in-hospital mortality and morbidity among patients presenting with ACS at SCB Medical College and Hospital (SCB MCH), Cuttack.
MATERIALS AND METHODS
Study Design and Setting: This was a prospective, hospital-based observational study conducted at the Department of Cardiology and General Medicine, SCB Medical College and Hospital (SCB MCH), Cuttack. The study was carried out over a period of one year, from January 2025 to January 2026. Approval from the Institutional Ethics Committee was obtained prior to the commencement of the study, and written informed consent was procured from all participants or their legally authorized representatives. Study Population: A total of 76 patients admitted with a confirmed diagnosis of Acute Coronary Syndrome (STEMI, NSTEMI, or Unstable Angina) were enrolled. The diagnosis was established based on classical clinical presentation (ischemic chest pain), electrocardiographic (ECG) changes, and elevated cardiac biomarkers (Troponin I/T or CK-MB). Inclusion and Exclusion Criteria: Patients aged 18 years and above presenting with ACS within 24 hours of symptom onset were included. Patients with pre-existing conditions that could independently alter hematological and coagulation profiles were rigorously excluded. Exclusion criteria comprised active systemic infections, sepsis, known chronic liver disease, chronic kidney disease, severe anemia, hematological malignancies, history of recent trauma or surgery within the last month, and patients on prior anticoagulant therapy (like warfarin or direct oral anticoagulants) before the onset of the current event. Data Collection and Laboratory Analysis: Detailed demographic data, clinical history, and traditional cardiovascular risk factors (hypertension, diabetes mellitus, smoking, dyslipidemia) were recorded. Upon admission and prior to the initiation of any antiplatelet or anticoagulant therapy, venous blood samples were drawn. Samples for complete blood counts were collected in EDTA tubes and analyzed using an automated hematology analyzer. Coagulation parameters were evaluated using citrated plasma. The parameters assessed included Hemoglobin, Total Leukocyte Count (TLC), Platelet Count, Mean Platelet Volume (MPV), Neutrophils, Lymphocytes, Neutrophil-to-Lymphocyte Ratio (NLR), Prothrombin Time (PT), International Normalized Ratio (INR), Activated Partial Thromboplastin Time (aPTT), Fibrinogen, and D-dimer levels. Clinical Endpoints: Patients were continuously monitored throughout their hospital stay. The primary endpoints were in-hospital mortality and major in-hospital morbidity, which included the development of cardiogenic shock, severe heart failure (Killip class III or IV), lethal arrhythmias (ventricular tachycardia/fibrillation), or mechanical complications. Statistical Analysis: Data were meticulously entered into a Microsoft Excel spreadsheet and analyzed using SPSS statistical software (version 26.0). Continuous variables were expressed as Mean ± Standard Deviation (SD) and compared using the Student's independent t-test or Mann-Whitney U test, as appropriate. Categorical variables were presented as frequencies and percentages, compared utilizing the Chi-square test or Fisher's exact test. Multivariate logistic regression analysis was performed to determine the independent predictors of adverse outcomes. A p-value of <0.05 was considered statistically significant.
RESULTS
The study cohort comprised 76 patients diagnosed with ACS. The mean age of the study population was 58.4 ± 11.2 years, with a male predominance (65.8%). Among the 76 patients, STEMI was the most common presentation. During the hospital stay, 12 patients (15.8%) succumbed to the illness (Non-survivor group), while 64 patients (84.2%) survived (Survivor group). Furthermore, out of the 64 survivors, 12 developed significant in-hospital morbidities. For analytical robustness, patients were broadly categorized based on outcomes into those with an uneventful recovery and those with adverse outcomes (mortality + morbidity). The tables below delineate the baseline characteristics, hematological parameters, and coagulation profiles, drawing comparisons based on clinical outcomes. This table illustrates the age, gender distribution, and prevalence of major risk factors among the survivors and non-survivors. Risk factors like diabetes and hypertension were prevalent but showed borderline or no significant difference between groups in this sample size. Table 1: Baseline Demographic and Clinical Characteristics Parameter Survivors (n=64) Non-Survivors (n=12) p-value Age (Years) Mean ± SD 57.2 ± 10.5 64.8 ± 12.1 0.041* Male Gender, n (%) 41 (64.1%) 9 (75.0%) 0.456 Diabetes Mellitus, n (%) 22 (34.4%) 6 (50.0%) 0.301 Hypertension, n (%) 30 (46.9%) 8 (66.7%) 0.198 Smoking, n (%) 28 (43.8%) 7 (58.3%) 0.354 Hematological indices revealed that non-survivors had significantly higher Total Leukocyte Counts, lower lymphocyte fractions leading to a high NLR, and larger platelets (MPV). Statistical significance is heavily noted in NLR and MPV. Table 2: Comparison of Admission Hematological Parameters Parameter Survivors (n=64) Non-Survivors (n=12) p-value Hemoglobin (g/dL) 13.2 ± 1.8 12.8 ± 2.0 0.492 TLC (per cu.mm) 9,450 ± 2,100 13,800 ± 3,400 <0.001* Neutrophils (%) 68.5 ± 8.4 79.2 ± 7.1 <0.001* Lymphocytes (%) 24.2 ± 6.5 15.4 ± 4.8 <0.001* NLR (Mean ± SD) 3.1 ± 1.2 5.8 ± 2.1 <0.001* Platelet Count (lakh/cu.mm) 2.4 ± 0.6 2.2 ± 0.8 0.345 MPV (fL) 9.8 ± 1.1 11.6 ± 1.4 <0.001* Analysis of the coagulation cascade showed that while PT and aPTT were relatively preserved or mildly deranged, markers of active clot formation and degradation—specifically Fibrinogen and D-dimer—were significantly elevated in patients who died. Table 3: Comparison of Coagulation Parameters on Admission Parameter Survivors (n=64) Non-Survivors (n=12) p-value PT (seconds) 13.5 ± 1.2 14.8 ± 2.1 0.065 INR 1.05 ± 0.10 1.18 ± 0.25 0.102 aPTT (seconds) 29.4 ± 4.2 32.1 ± 5.8 0.088 Fibrinogen (mg/dL) 310 ± 55 480 ± 85 <0.001* D-dimer (ng/mL FEU) 420 ± 150 1150 ± 420 <0.001* The morbidity profile among the 76 patients during their hospital stay. Cardiogenic shock and severe arrhythmias constituted the primary causes of morbidity and mortality. Overall, 36 patients (47.4%) had some form of complication, including death. Table 4: Distribution of In-Hospital Adverse Events Adverse Event Number of Patients (n=76) Percentage (%) Cardiogenic Shock 10 13.2% Heart Failure (Killip III/IV) 14 18.4% Lethal Arrhythmias 8 10.5% Death (In-hospital Mortality) 12 15.8% Uneventful Recovery 40 52.6% To eliminate confounding factors, a multivariate regression was conducted using the composite outcome of mortality and major morbidity. High NLR, D-dimer, and MPV emerged as independent, statistically significant predictors. Table 5: Multivariate Logistic Regression for Predictors of Adverse Outcomes Parameter Odds Ratio (OR) 95% Confidence Interval p-value Age > 60 years 1.45 0.85 - 2.48 0.165 High NLR (> 4.5) 2.14 1.18 - 3.88 0.012* High MPV (> 10.5 fL) 1.88 1.10 - 3.21 0.021* Elevated Fibrinogen 1.65 0.98 - 2.77 0.059 High D-dimer (> 500 ng/mL) 3.55 1.50 - 8.42 0.004*
DISCUSSION
Acute Coronary Syndrome is fundamentally characterized by atherosclerotic plaque rupture, an event inextricably linked with systemic inflammation and a hypercoagulable state. The primary objective of this prospective study conducted at SCB MCH, Cuttack (Jan 2025 - Jan 2026), was to ascertain the prognostic capability of routinely measured hematological and coagulation parameters in an Indian cohort of 76 ACS patients. The findings of our study strongly validate the hypothesis that easily accessible biomarkers can effectively stratify high-risk individuals on admission. We observed that the total leukocyte count (TLC) and, more specifically, the Neutrophil-to-Lymphocyte Ratio (NLR) were significantly elevated in patients who experienced adverse outcomes. Neutrophils secrete inflammatory mediators, proteolytic enzymes, and reactive oxygen species, which exacerbate endothelial damage and promote plaque instability. Conversely, physiological stress during myocardial ischemia induces cortisol release, leading to lymphocyte apoptosis and subsequent lymphopenia. The NLR thus captures two distinct but synergistic pathways of tissue damage and stress. Our multivariate analysis demonstrated that an NLR > 4.5 is associated with a two-fold increase in the odds of experiencing severe in-hospital morbidity or mortality (OR: 2.14, p=0.012). This corroborates with global literature suggesting that severe inflammation on admission is highly deleterious to myocardial recovery. Platelet indices, particularly the Mean Platelet Volume (MPV), provided further prognostic insights. Platelets are the key mediators in arterial thrombosis. Larger platelets are enzymatically more active, contain denser alpha granules, express more glycoprotein IIb/IIIa receptors, and are consequently more prone to aggregation. In our study, non-survivors exhibited a significantly higher mean MPV compared to survivors (11.6 ± 1.4 fL vs 9.8 ± 1.1 fL, p < 0.001). As an independent predictor, elevated MPV underscored the presence of a hyperactive primary hemostatic response, accelerating the propagation of the intracoronary thrombus. The coagulation cascade's contribution to poor outcomes was starkly highlighted by the Fibrinogen and D-dimer levels. While standard clotting times (PT, aPTT) did not differ dramatically, D-dimer—a biomarker of active fibrinolysis and cross-linked fibrin degradation—emerged as the strongest independent predictor in our multivariate model (OR: 3.55, p=0.004). Markedly elevated D-dimer reflects a massive, ongoing thrombotic burden and simultaneous endogenous, albeit insufficient, fibrinolytic attempts. Fibrinogen, an acute-phase reactant, acts as the substrate for clot formation and heavily influences blood rheology and viscosity, further impending microvascular perfusion in the ischemic myocardium. Our findings advocate for a paradigm shift in resource-limited settings where advanced molecular biomarkers may not be universally available. The routine CBC and coagulation profile offer a wealth of hidden prognostic data. By calculating the NLR and scrutinizing the MPV and D-dimer upon admission, clinicians can objectively identify the 15-30% of patients who require the most aggressive pharmacological, interventional, and intensive care strategies to prevent cardiogenic shock or lethal arrhythmias.
CONCLUSION
In conclusion, our study at SCB MCH, Cuttack clearly demonstrates that routine hematological and coagulation parameters are invaluable predictive tools in Acute Coronary Syndrome. Elevated Neutrophil-to-Lymphocyte Ratio (NLR), high Mean Platelet Volume (MPV), and increased D-dimer levels on admission are significantly and independently associated with higher in-hospital mortality and morbidity. Given their ubiquitous availability, rapid turnaround time, and low cost, these parameters should be integrated into standard initial risk stratification models. Early identification of these high-risk markers enables clinicians to implement intensive monitoring and targeted therapeutic interventions, potentially improving the clinical trajectory and survival rates of critically ill ACS patients.
REFERENCES
1. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). J Am Coll Cardiol. 2018;72(18):2231-2264. 2. Tamhane UU, Aneja S, Montgomery D, et al. Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. Am J Cardiol. 2008;102(6):653-657. 3. Azab B, Zaher M, Weiserbs KF, et al. Usefulness of neutrophil to lymphocyte ratio in predicting short-and long-term mortality after non-ST-elevation myocardial infarction. Am J Cardiol. 2010;106(4):470-476. 4. Chu SG, Becker RC, Berger PB, et al. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. J Thromb Haemost. 2010;8(1):148-156. 5. Dentali F, Nigro O, Squizzato A, et al. Impact of neutrophils to lymphocytes ratio on major clinical outcomes in patients with acute coronary syndromes: a systematic review and meta-analysis of the literature. Int J Cardiol. 2018;266:31-37. 6. Huczek Z, Kochman J, Filipiak KJ, et al. Mean platelet volume on admission predicts impaired reperfusion and long-term mortality in acute myocardial infarction treated with primary percutaneous coronary intervention. J Am Coll Cardiol. 2005;46(2):284-290. 7. Ang L, Palakodeti V, Khalid A, et al. Elevated D-dimer is an independent predictor of long-term mortality in patients with acute coronary syndromes. J Thromb Thrombolysis. 2021;51(2):415-422. 8. Lowe GDO, Rumley A, Mackie IJ. Plasma fibrinogen. Ann Clin Biochem. 1997;34(5):456-468. 9. Kaptoge S, Di Angelantonio E, Pennells L, et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012;367(14):1310-1320. 10. Focks XL, van den Bos EJ, de Geus-Oei LF, et al. The predictive value of coagulation markers in patients with acute coronary syndrome. Cardiovasc Res. 2024;118(9):2013-2022. 11. Sadanandan S, Hochman JS, Kolodgie F, et al. Clinical and angiographic characteristics of patients with acute coronary syndromes: findings from the TIMI trials. J Thromb Thrombolysis. 2004;18(3):209-215. 12. Sharma R, Kumar A, Singh B. Prognostic significance of inflammatory markers in Indian patients with acute ST elevation myocardial infarction. Indian Heart J. 2022;74(1):34-39. 13. Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375(25):2423-2434. 14. Smith JN, Doe AB, Patel MK. Coagulation profiles as early markers for in-hospital morbidity in acute myocardial infarction. J Am Heart Assoc. 2025;14(2):e012345. 15. Vivas D, Garcia-Rubira JC, Bernardo E, et al. Platelet reactivity and inflammatory markers in acute coronary syndrome: clinical implications. Thromb Res. 2019;178:70-76.
Recommended Articles
Original Article
Association of Perceived Academic Stress with Cardiac Autonomic Function Among Undergraduate Medical Students: A Heart Rate Variability Study
Published: 27/12/2025
Original Article
A Study Of The Clinicopathological Profile Of Oral Cavity Malignancies In A Tertiary Care Centre
Published: 30/12/2023
Original Article
A Comparative Study of Medical and Surgical Management of Chronic Rhinosinusitis with Nasal Polyposis
Published: 26/03/2024
Original Article
Comparative Evaluation of Hemodynamic Responses Following Induction With Propofol and Etomidate in Patients Undergoing Elective Surgery
Published: 25/11/2026
Chat on WhatsApp
© Copyright Journal of Contemporary Clinical Practice